Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.8K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

1.0K
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
1.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

1.7K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.7K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.9K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

1.2K
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
1.2K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrative Clinical-Molecular Modeling Identifies <i>LRRN4CL</i> as a Determinant of Structural and Functional Myocardial Improvement.

bioRxiv : the preprint server for biology·2026
Same author

The Role of Sphingolipids in Myocardial Recovery Mediated by Mechanical Unloading and Circulatory Support.

JACC. Basic to translational science·2025
Same author

Association of Kidney Function With Myocardial Recovery and Adverse Events Following Left Ventricular Assist Device Circulatory Support.

Journal of the American Heart Association·2025
Same author

CMR and adverse clinical outcomes in peripartum cardiomyopathy.

American heart journal plus : cardiology research and practice·2024
Same author

Integration of Patient Reported Quality-of-life Data into Risk Assessment in Heart Failure.

Journal of cardiac failure·2024
Same author

Lack of Association Between Donor-Derived Cell-Free DNA and Cardiac Allograft Vasculopathy.

Clinical transplantation·2024
Same journal

Prosthetic valve thrombosis: contemporary concepts in diagnosis and management.

Expert review of cardiovascular therapy·2026
Same journal

Life's essential 8 and its role in cardiovascular health: evolution, evidence, and future directions.

Expert review of cardiovascular therapy·2026
Same journal

Efficacy and safety of clopidogrel and aspirin initiated within 72 hours after mild ischemic stroke or high-risk TIA by sex: a prespecified subgroup analysis of the INSPIRES trial.

Expert review of cardiovascular therapy·2026
Same journal

Approaches to transcatheter aortic valve replacement failure: is more focus on prevention required?

Expert review of cardiovascular therapy·2026
Same journal

Vericiguat for heart failure with reduced ejection fraction: a perspective from approval to real-world clinical treatment.

Expert review of cardiovascular therapy·2026
Same journal

Early autonomic neuropathy in prediabetes: an overlooked driver of cardiometabolic risk.

Expert review of cardiovascular therapy·2026
See all related articles

Related Experiment Video

Updated: May 1, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.1K

Heart failure with preserved ejection fraction.

Mershed Alsamara1, Rami Alharethi

  • 1Cardiovascular Division, Heart Institute, Providence Hospitals and medical Center 16001 West 9 mile road, Southfield, MI 48075, USA.

Expert Review of Cardiovascular Therapy
|April 22, 2014
PubMed
Summary
This summary is machine-generated.

Heart failure with preserved ejection fraction (HFpEF) affects many hospitalized patients. Current treatments focus on managing symptoms and comorbidities, as its complex causes require further research for targeted therapies.

Keywords:
HFpEFcardiomyopathydiastolic dysfunctionpreserved ejection fraction

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.2K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.3K

Related Experiment Videos

Last Updated: May 1, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.1K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.2K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.3K

Area of Science:

  • Cardiology
  • Internal Medicine

Background:

  • Heart failure with preserved ejection fraction (HFpEF) represents up to 50% of heart failure hospitalizations.
  • HFpEF is linked to substantial mortality and morbidity.
  • The underlying pathophysiology of HFpEF is complex and not fully understood.

Purpose of the Study:

  • To summarize the current understanding of HFpEF.
  • To outline current management principles for HFpEF.
  • To highlight the need for further research into HFpEF pathophysiology.

Main Methods:

  • Literature review and synthesis of existing knowledge on HFpEF.
  • Analysis of current treatment guidelines and research trends.
  • Identification of knowledge gaps in HFpEF pathophysiology.

Main Results:

  • HFpEF is a heterogeneous condition with poorly defined pathophysiology.
  • Current management strategies primarily involve volume control (diuretics, diet) and comorbidity management (hypertension).
  • There is a lack of disease-specific therapies for HFpEF.

Conclusions:

  • Effective HFpEF treatment requires addressing its heterogeneous nature.
  • Further research is crucial to identify specific molecular and cellular targets for novel therapies.
  • Understanding the key pathophysiological components is essential for developing targeted treatments.